quantisnow
FeedTopReportsPricing
⌘K
Live feed
10:06:19·136d
INSIDERFiling
Akero Therapeutics Inc. logo

Director Henderson Jane returned 9,398 shares to the company, closing all direct ownership in the company (SEC Form 4)

AKRO· Akero Therapeutics Inc.
Health Care
Original source

Companies

  • AKRO
    Akero Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Sep 4UpdateH.C. Wainwright$72.00
  • Aug 4UpdateTD Cowen$76.00
  • Jan 30UpdateBofA Securities$63.00
  • Jan 27UpdateH.C. Wainwright$72.00
  • Nov 18UpdateCitigroup$65.00
  • Apr 22UpdateBofA Securities$30.00

Related

  • SEC125d
    SEC Form 15-12G filed by Akero Therapeutics Inc.
  • SEC135d
    SEC Form 25-NSE filed by Akero Therapeutics Inc.
  • INSIDER135d
    Director Heyman Tomas J. returned 9,398 shares to the company, closing all direct ownership in the company (SEC Form 4)
  • INSIDER135d
    Director Xu Yuan returned 9,398 shares to the company, closing all direct ownership in the company (SEC Form 4)
  • INSIDER135d
    President and CEO Cheng Andrew returned 436,837 shares to the company, closing all direct ownership in the company (SEC Form 4)
  • INSIDER135d
    Director Harrison Seth Loring returned 293,762 shares to the company, closing all direct ownership in the company (SEC Form 4)
  • INSIDER135d
    Director Graham G. Walmsley returned 1,302,398 shares to the company, closing all direct ownership in the company (SEC Form 4)
  • INSIDER135d
    Director Judy Chou returned 9,398 shares to the company, closing all direct ownership in the company (SEC Form 4)
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022